Related Experiment Video

Updated: Mar 13, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NO

Robert J Fox1

  • 1Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|October 13, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

11.0K

Related Experiment Videos

Last Updated: Mar 13, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

11.0K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

5.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K

Articles linked to this work by shared authors, journal, and citation graph.

Assessing the feasibility, theoretical interest, and observed behaviors of adding genetic data to a patient-reported multiple sclerosis registry.

Multiple sclerosis journal - experimental, translational and clinical·2026

Clinicians' and patients' perspectives of a mobility technician role in the hospital to promote ambulation: A qualitative study.

Journal of hospital medicine·2026

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.

Multiple sclerosis and related disorders·2026

Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases.

Multiple sclerosis journal - experimental, translational and clinical·2026

Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data.

Expert opinion on investigational drugs·2026

Men's health research priorities in men with multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026

Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Increased autoimmune disease burden before multiple sclerosis and neuromyelitis optica spectrum disorder diagnosis: A nationwide Korean cohort study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Who declines neurocognitive testing? A cross-sectional study in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Validation of generative artificial intelligence techniques for synthetic data generation in multiple sclerosis research: A comparison with real-world evidence from the Italian multiple sclerosis registry.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Survivor bias and disease progression in observational cohorts in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

How well do junior neurology residents recognize multiple sclerosis? Analysis of the "Close the Loop" resident clinical acumen project.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC.

JTO clinical and research reports·2026

Correction: GOLPH3 inhibits glioma cell apoptosis through the JNK signaling pathway.

Frontiers in genetics·2026

Application of Dual-Targeting Carbon Dot Nanozymes in Improving Hypoxia and Enhancing Small Interfering RNA-Mediated Gene Silencing for Hepatocellular Carcinoma.

Biomaterials research·2026

First demonstration of benzosultam CRBN ligand-mediated PROTACs for BTK and BRD4 degradation.

RSC medicinal chemistry·2026

Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.

Materials today. Bio·2026

Why only 3 months? Immunological constraints on CAR-T therapy in gastrointestinal cancers.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us